A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 [oregovomab] in Patients With Ovarian Epithelial Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 17 Dec 2007
At a glance
- Drugs Oregovomab (Primary)
- Indications Ovarian cancer
- Focus Pharmacokinetics
- 17 Dec 2007 Status changed from in progress to discontinued.
- 25 Sep 2005 New trial record.